全文获取类型
收费全文 | 26732篇 |
免费 | 1653篇 |
国内免费 | 143篇 |
专业分类
耳鼻咽喉 | 219篇 |
儿科学 | 680篇 |
妇产科学 | 489篇 |
基础医学 | 2966篇 |
口腔科学 | 435篇 |
临床医学 | 2443篇 |
内科学 | 5864篇 |
皮肤病学 | 364篇 |
神经病学 | 1473篇 |
特种医学 | 723篇 |
外国民族医学 | 4篇 |
外科学 | 4811篇 |
综合类 | 850篇 |
现状与发展 | 1篇 |
一般理论 | 27篇 |
预防医学 | 1894篇 |
眼科学 | 703篇 |
药学 | 2575篇 |
中国医学 | 339篇 |
肿瘤学 | 1668篇 |
出版年
2023年 | 327篇 |
2022年 | 926篇 |
2021年 | 1229篇 |
2020年 | 746篇 |
2019年 | 959篇 |
2018年 | 1077篇 |
2017年 | 713篇 |
2016年 | 661篇 |
2015年 | 796篇 |
2014年 | 1097篇 |
2013年 | 1331篇 |
2012年 | 2011篇 |
2011年 | 1977篇 |
2010年 | 1085篇 |
2009年 | 867篇 |
2008年 | 1456篇 |
2007年 | 1418篇 |
2006年 | 1277篇 |
2005年 | 1184篇 |
2004年 | 1041篇 |
2003年 | 946篇 |
2002年 | 728篇 |
2001年 | 581篇 |
2000年 | 523篇 |
1999年 | 415篇 |
1998年 | 163篇 |
1997年 | 124篇 |
1996年 | 119篇 |
1995年 | 120篇 |
1994年 | 66篇 |
1993年 | 86篇 |
1992年 | 206篇 |
1991年 | 191篇 |
1990年 | 167篇 |
1989年 | 175篇 |
1988年 | 142篇 |
1987年 | 156篇 |
1986年 | 124篇 |
1985年 | 140篇 |
1984年 | 117篇 |
1983年 | 92篇 |
1982年 | 64篇 |
1981年 | 72篇 |
1979年 | 97篇 |
1978年 | 68篇 |
1977年 | 67篇 |
1975年 | 62篇 |
1974年 | 51篇 |
1973年 | 55篇 |
1972年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
BACKGROUND: We assessed suicide and suicide attempt risk as well as symptom reduction among 3,282 depressed patients participating in duloxetine and escitalopram clinical trials assigned to either an antidepressant or placebo. METHODS: We reviewed the FDA Summary Basis of Approval reports for data regarding safety and efficacy for duloxetine and escitalopram. Furthermore, we compared suicide risk among antidepressant clinical trials in this study with our two previous analyses on seven antidepressant clinical trials. RESULTS: Suicide and suicide attempt risk varied considerably among the three analyses, showing up to ten fold differences. Interestingly, the variability exists across the three reports, rather than between treatments (antidepressants versus placebo). CONCLUSIONS: These findings suggest caution in generalizing suicide risk even from a relatively large number of participants and thus, firm conclusions can only be drawn if the number of participants is overwhelmingly large (approximately two million patients). We also noted similar magnitude of response to placebo and antidepressants among the three studies. 相似文献
52.
Muhammad F Dawwas James D Lewsey James M Neuberger Alexander E Gimson 《Liver transplantation》2007,13(8):1115-1124
Modification of the current allocation system for donor livers in the United States to incorporate recipient serum sodium concentration ([Na]) has recently been proposed. However, the impact of this parameter on posttransplantation mortality has not been previously examined in a large risk-adjusted analysis. We assessed the effect of recipient [Na] on the survival of all adults with chronic liver disease who received a first single organ liver transplant in the UK and Ireland during the period March 1, 1994 to March 31, 2005 (n=5,152) at 3 years, during the first 90 days, and beyond the first 90 days, adjusting for a wide range of recipient, donor, and graft characteristics. Compared to those with normal [Na] (135-145 meq/L; n=3,066), severely hyponatremic recipients ([Na]<130 meq/L, n=541), had a higher risk-adjusted mortality at 3 years (hazard ratio [HR] 1.28; 95% confidence interval [CI], 1.04-1.59; P<0.02). The excess mortality was, however, confined to the first 90 days (HR 1.55; 95% CI, 1.18-2.04; P<0.002) with no significant difference thereafter. This was also true for hypernatremic recipients ([Na]>45 meq/L, n=81), who had an even greater risk-adjusted mortality compared to normonatremic recipients (overall: HR 1.85; 95% CI, 1.25-2.73; P<0.002; 90 days: HR 1.12; 95% CI, 0.55-2.29; P=0.8), whereas mildly hyponatremic recipients ([Na] 130-134 meq/L, n=1,127) had similar risk-adjusted mortality to those with normal [Na] at the same time points. In conclusion, recipient [Na] is an independent predictor of death following liver transplantation. Attempts to correct the [Na] toward the normal reference range are an important aspect of pretransplantation management. 相似文献
53.
Steven J. Davidson MD MBA Frank L. Zwemer Jr. MD MBA Larry A. Nathanson MD Kenneth N. Sable MD Abu N.G.A. Khan MD MS 《Academic emergency medicine》2004,11(11):1127-1134
Physician-generated emergency department clinical documentation (information obtained from clinician observations and summarized decision processes inclusive of all manner of electronic systems capturing, storing, and presenting clinical documentation) serves four purposes: recording of medical care and communication among providers; payment for hospital and physician; legal defense from medical negligence allegations; and symptom/disease surveillance, public health, and research functions. In the consensus development process described by Handler, these objectives were balanced with the consideration of efficiency, often evaluated as physician time and clinical documentation system costs, in recording the information necessary for their accomplishment. The consensus panel session participants and authors recommend that 1) clinical documentation be electronically retrievable; 2) selection and implementation be evidence-based and grounded on valid metrics (research is needed to identify these metrics); 3) the user interface be crafted to promote clinical excellence through high-quality information collection and efficient charting techniques; 4) the priorities for integration of clinical information be standardized and implemented within enterprises and across health and information systems; 5) systems use accepted standards for bidirectional, real-time clinical data exchange, without limiting the location or number of simultaneous users; 6) systems fully utilize existing electronic sources of specific patient information and general medical knowledge; 7) systems automatically and reliably capture appropriate data that support electronic billing for emergency department services; and 8) systems promote bedside documentation and mobile access. 相似文献
54.
Eight cases of spinal brucellosis are included in this study. Diagnosis was established by positive serology. Back pain was the most common complaint. Functional disturbance in walking was observed in three cases; in two others this was because of impairment of cord function. Clinical hepatosplenomegaly was found in one case. Subclinical organomegaly was diagnosed in two other patients. Psoas abscess was identified by computed tomographic scan in two separate cases. Response to drug therapy and surgical decompression, when indicated, resulted in complete recovery in all patients. 相似文献
55.
56.
57.
58.
59.
Comorbidities in head and neck cancer: agreement between self-report and chart review. 总被引:1,自引:1,他引:0
Shraddha S Mukerji Sonia A Duffy Karen E Fowler Mumtaz Khan David L Ronis Jeffrey E Terrell 《Otolaryngology--head and neck surgery》2007,136(4):536-542
OBJECTIVES: To determine the accuracy of self-reported comorbidities compared with medical record review and the clinical and sociodemographic characteristics associated with accuracy of self-reported comorbidities. STUDY DESIGN: We conducted a prospective study of 458 newly diagnosed head and neck cancer patients using self-administered questionnaire and medical chart review data. Overall and itemwise consistency between self-report and chart review was evaluated. Social, clinical, and demographic characteristics of consistent versus inconsistent responders were analyzed. RESULTS: Seventy-four percent of patients had at least one comorbidity. There was good overall consistency between self-report and chart review (kappa = 0.50). Compared with consistent responders, inconsistent responders were found to be older (P < 0.05), have lower sleep (P < 0.05) and physical activity scores (P < 0.05), be more depressed (P < 0.05), and have more severe comorbidities (P < 0.05). CONCLUSIONS AND SIGNIFICANCE: Self-report may be considered as an alternative to chart review for comorbidity assessment in head and neck cancer patients. Younger patients, those with good general health, fewer depressive symptoms, and mild comorbidities, are more likely to give responses consistent with chart review. 相似文献
60.
Seema Khan Smita Singhal Tarun Mathur Dilip J Upadhyay Ashok Rattan 《Nippon Ishinkin Gakkai Zasshi》2007,48(3):109-113
Disulfiram, an alcohol antagonistic drug has been on the market since 1949 with 80% bioavailability and an established safety profile. Recently it has been reported as a P-glycoprotein efflux pump modulator. Herein we report its antifungal potential. The MIC50 and MIC90 of disulfiram for yeast isolates is 4 and 8 microg/ml, respectively, and the MIC range is 1-16 micro g/ml for both fluconazole sensitive and resistant strains. Interestingly, disulfiram also showed fungicidal activity on Aspergillus spp. with MIC50 and MIC90 of 2 and 8 microg/ml, respectively. 相似文献